



05-05-05

IFW

Express Mail No.: EV 544892835 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dingivan

Confirmation No.: 7146

Application No.: 10/091,313

Group Art Unit: 1616

Filed: March 4, 2002

Examiner: To Be Assigned

For: METHODS OF PREVENTING OR
TREATING INFLAMMATORY OR
AUTOIMMUNE DISORDERS BY
ADMINISTERING CD2 ANTAGONISTS
IN COMBINATION WITH OTHER
PROPHYLACTIC OR THERAPEUTIC
AGENTS

Attorney Docket No.: 10271-063-999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the United States Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to references B15 to B23, and C01 to C151 listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references B15 to B23, and C01 to C151 are enclosed herewith.

While not to be construed as indicating that the Examiner should not fully consider the listed references, the Examiner's attention is particularly directed to the following references: B16, B17, B18, B19, C23, C24, C32, C36, C39, C40, C45, C47, C48, C50, C59, C70, C74, C79, C84, C85, C87, C89, C90-C93, C95, C97, C100, C104, C116, C119, C122, C124, C126, C127, C128, C132, C144 and C146.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(3), Applicants believe that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed.

Respectfully submitted,


Date: May 3, 2005

Anthony M. Insogna 35,203
Anthony M. Insogna (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

Enclosures

By: Jennifer J. Chedea
Reg No. 46,617

	LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY. DOCKET NO. 10271-063-999	APPLICATION NO. 10/091,313
	APPLICANT Dingivan			
	FILING DATE March 4, 2002		GROUP 1616	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	B15	WO 96/04388	2/15/96	PCT		
	B16	WO 94/20619	9/15/94	PCT		
	B17	WO 93/06866	4/15/93	PCT		
	B18	WO 93/06852	4/15/93	PCT		
	B19	WO 92/16622	10/1/92	PCT		
	B20	WO 89/05155	6/15/89	PCT		
	B21	EP 555880	8/18/93	EP		
	B22	EP 394827	10/31/90	EP		
	B23	EP 367166	5/9/90	EP		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Dialog Accession No.: 469651, CEABA Accession No.: 30-12-019253. Medimmune Biotransplant Trial Results. Biotechnology Newswatch, 19 July 1999
C02	GenBank AF018081 Human type XVIII collagen (COL18A1) m RNA, alternatively spliced, long form, complete cds
C03	GenBank AF018082 Human type XVIII collagen (COL18A1) m RNA, alternatively spliced, short form, complete cds
C04	GenBank AH002740 human T-cell surface antigen T11 (CD2) gene, exon 1, clone PB2
C05	GenBank CAA29622
C06	GenBank E12817 cDNA encoding human LFA-3
C07	GenBank M16445 human surface antigen CD2 mRNA, complete cds
C08	GenBank NM_000301 human plasminogen (PLG), mRNA
C09	GenBank NM_000948 human prolactin (PRL), mRNA
C10	GenBank X06143 murine mRNA for T11 protein
C11	Abrams et al., 2000, "Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells," J. Exp. Med. 192(5):681-694
C12	Adkins et al., 2000, "A phase I placebo-controlled, randomized, dose-escalation safety study of MEDI-507, a humanized anti-DC2 monoclonal antibody, in the initial treatment of at least grade II acute graft-versus host disease," Blood 96:476A
C13	Ames et al., 1995, "Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins," J. Immunol. Methods 184:177-186
C14	Anasetti et al., 2000, "Anti-CD3 F(AB') ₂ prevents Graft-Versus-Host Disease by selectively depleting donor T cells activated by recipient alloantigens," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00
C15	Arnon et al., 1985, "Monoclonal antibodies for immunotargeting of drugs in cancer therapy," in: <i>Monoclonal Antibodies and Cancer Therapy</i> , Reisfeld et al., eds., Alan R. Liss, Inc., pp. 243-256
C16	Asadullah et al., 1999, "Interleukin-10 in Cutaneous Disorders: Implications for Its Pathophysiological Importance and Therapeutic Use," Arch. Dermatol. Res. 291(12):628-36
C17	Ashcroft et al., 2000, "Therapeutic strategies for psoriasis," J. Clin. Pharm. Ther. 25:1-10
C18	Ashkenazi et al., 1991, "Protection against endotoxic shock by a tumor necrosis factor receptor immunoaderin," Proc. Natl. Acad. Sci. USA 88:10535-10539
C19	Ausubel et al., eds., 1999, <i>Current Protocols in Molecular Biology</i> , John Wiley & Sons, NY, pp. 2.10.3 and 6.3.1 - 6.3.6
C20	Baldwin et al., eds., 1985, "Analysis, results and future prospective of the therapeutic use of radiolabeled antibody in cancer therapy," in: <i>Monoclonal Antibodies for Cancer Detection and Therapy</i> , Academic Press, pp. 303-316

C21	Bathon et al., 2000, "A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis," N. Eng. J. Med. 343:1586-1602
C22	Bauer et al., 1999, "Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis," J. Pharmacokinetics Biopharmaceutics 27:397-420
C23	Besse et al., 1997, "Prevention of Rejection with BTI-322 After Renal Transplantation (Results at 9 Months)" Transplantation Proc. 29:2425-2426
C24	Branco et al., 1999, "Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells," Transplantation 68:1588-1596
C25	Buchwald et al., 1980, "Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis," Surgery 88:507-516
C26	Camisa, 2000, "Psoriasis: A Clinical Update on Diagnosis and New Therapies," Cleve Clin. J. Med. 67(2):105-106
C27	Cao et al., 1996, "Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells," J. Biol. Chem. 271:29461-29467
C28	Carpenter et al., 2000, "Humanized non-FCR-binding anti-CD3 antibody as therapy for glucocorticoid refractory acute GVHD," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Location 305
C29	Carrell, 1999, "How serpins are shaping up," Science 285:1861-1862
C30	Cathcart et al., 1986, "Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen," Lab. Invest. 54:26-31
C31	Chiorazzi, 1986, "Human monoclonal antibodies as probes to study autoimmune and allergic disorders," Biotechnology 4:210-218
C32	Chisholm et al., 1994, "The effects of an immunomodulatory LFA3-IgG ₁ fusion protein on nonhuman primates," Therapeutic Immunity 1:205-216
C33	Chong, 1996, "Receptors that turn on and turn off natural killer cells," J Heart Lung Transplant. 15(7):675-683
C34	Cleek et al., 1997, Proc. Intl. Symp. Control. Rel. Bioact. Mater. 24:853-854
C35	Cohn et al., 1997, "Induction of airway mucus production By T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production," J. Exp. Med. 186:1737-1747
C36	Couriel et al., 2000, "Infliximab for the treatment of Graft-Versus-Host disease in allogeneic transplant recipients: an update," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Poster Board Number 775
C37	Courtenay et al., 1980, "Immunisation against heterologous type II collagen induces arthritis in mice," Nature 283:666-668
C38	Crowley et al., 1993, "Prevention of metastasis by inhibition of the urokinase receptor," Proc. Natl. Acad. Sci. USA 90:5021-5025
C39	Davis et al., 1996, "The Structure and Ligand Interactions of CD2: Implications for T-Cell Function," Immunology Today 17(4):177-187
C40	Dehoux et al., 2000, "Effects on human and nonhuman primate immune response of a new rat anti-CD2 monoclonal antibody," Transplantation 69:2622-2633
C41	Devrimci-Ozguven et al., 2000, "The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients," J. Eur. Acad. Dermatol. Venereol. 14:267-271
C42	Diasio et al., 1996, "Immunomodulators: Immunosuppressive agents and immunostimulants," in: The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, Ch. 52, pp. 1291-1306
C43	DiSepio et al., 2000, "New Drugs in the Treatment of Psoriasis," Expert Opin Investig Drugs 9(1):79-93
C44	Drew, 2000, "Psoriasis," Primary Care 27:385-406
C45	Dumont et al., 1998, "Potent apoptotic signaling and subsequent unresponsiveness induced by a single CD2 mAb (BTI-322) in activated human peripheral T Cells," J. Immunol. 3797-3804
C46	Durie et al., 1994, "The role of CD40 in the regulation of humoral and cell-mediated immunity," Immunol. Today 15:406-411
C47	Ellis, 1999, "Quality of Life (QOL) of Amevive™ (LFA3TIP) in patients with chronic plaque psoriasis," Amevive Breakfast Meeting, 12/3/99 and abstract from Br. J. Dermatol. 141:990 Abstract 82
C48	Ellis et al., "Quality of Life (QOL) in Patients with Chronic Psoriasis Treated with AMEVIVE (LFA3TIP)," Poster Presentation
C49	Feldmann, M. 'Cytokine Inhibitors: Biologics'. In: Inflammation: Basic Principles and Clinical Correlates. 3 rd Edition, Ed. Gillian and Synderman. Lippincott Williams & Wilkins (Philadelphia) 1999, pages 1207-1212
C50	Ferrant et al., 1997, "LO-CD2a/BTI322 for Steroid Resistant Graft-Versus-Host Disease," BTI Ref 1979, (Something) Transplant 19(Supp. 1): S181 Abstract P721
C51	Flanders et al., 1999, "Prevention of type 1 diabetes from laboratory to public health," Autoimmun. 29:235-246
C52	Foster, 1999, "Relevance of systemic lupus erythematosus nephritis animal models to human disease," Semin. Nephrol. 19:12-24
C53	Fredriksson and Pettersson, 1978, "Severe psoriasis--oral therapy with a new retinoid," Dermatologica 157:238-244
C54	Goodson et al., 1994, "High-affinity urokinase receptor antagonists identified with bacteriophage peptide display," Proc. Natl. Acad. Sci. USA 91:7129-7133
C55	Goodson, 1984, "Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis," in: <i>Medical Applications of Controlled Release</i> , vol. 2, pp. 115-138
C56	Gottlieb et al., 2000, "Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study," J. Am. Acad. Dermatol. 43:595-604

C57	Gottlieb et al., 2000, "Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis," J. Am. Acad. Dermatol. 42:428-435
C58	Greaves and Weinstein, 1995, "Treatment of psoriasis," N. Eng. J. Med. 332:581-588
C59	Griffiths, 1999, "T cell targeting for psoriasis," Amevive Breakfast Meeting, 12/3/99
C60	Guzzo et al., 1996, "Dermatological pharmacology," in: The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, Hardman et al., eds., Ch. 64, pp. 1593-1613
C61	Hansra et al., 2000, "Carrageenan-induced arthritis in the rat," Inflammation 24:141-155
C62	Harari et al., 2000, "Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead-Sea," Int. J. Dermatol. 39:913-918
C63	Hellstrom et al., 1987, "Antibodies for drug delivery," in: <i>Controlled Drug Delivery 2nd</i> ed., Robinson et al., eds., Marcel Dekker, Inc. pp. 623-653
C64	Heslop et al., 2000, "ABX-CBL monoclonal antibody in patients with steroid resistant graft versus host disease," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Abstract 305
C65	Holmdahl, 1999, "Autoimmunity: Another pathway towards arthritis," Curr. Biol. 9:R528-530
C66	Howard et al., 1989, "Intracerebral drug delivery in rats with lesion-induced memory deficits," J. Neurosurg. 71:105-112
C67	Husted et al., 1995, "A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis," Clin. Exp. Rheumatol. 13:439-443
C68	Jemec and Wulf, 1997, "The applicability of clinical scoring systems: SCORAD and PASI in psoriasis and atopic dermatitis," Acta Derm. Venereol. 77:392-393
C69	Jooss et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung," Hum. Gene Ther. 7:1555-1566
C70	Kaplon et al., 1996, "Short Course Single Agent Therapy with an LFA-3-IgG1 Fusion Protein Prolongs Primate Cardiac Allograft Survival," Transplantation 61(3):356-363
C71	Karasek, 1999, "Progress in our understanding of the biology of psoriasis," Cutis 64:319-322
C72	Kim and Berstad, 1992, "Experimental colitis in animal models," Scand. J. Gastroenterol. 27:529-537
C73	Kohno et al., 1990, "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor," Proc. Natl. Acad. Sci. USA 87:8331-8335
C74	Kozarsky et al., 1993, "An anti-CD2 monoclonal antibody that both inhibits and stimulates T cell activation recognizes a subregion of CD2 distinct from known ligand-binding sites," Cell Immunol. 150:235-246
C75	Krieger et al., 1997, "The use of CD4 and CD8 knockout mice to study the role of T-cell subsets in allotransplant rejection," J. Heart Lung Transplant. 16:263-267
C76	Krogh et al., 1999, "Models to study the pathogenesis of thyroid autoimmunity," Biochimie 81:511-515
C77	Krueger et al., 2000, "Anti-CD11a Treatment for Psoriasis Concurrently Increases Circulating T-cells and Decreases Plaque T-cells, Consistent with Inhibition of Cutaneous T-cell Trafficking," J. Invest. Dermatol. 115(2):333
C78	Krueger et al., 2000, "Successful in vivo Blockade of CD25 (High-Affinity Interleukin 2 Receptor) on T Cells by Administration of Humanized Anti-Tac Antibody to Patients with Psoriasis," J. Am. Acad. Dermatol. 43(3):448-458
C79	Krueger, 1999, "Efficacy and safety results of a phase II trial with LFA3TIP in patients with chronic plaque psoriasis," Amevive Breakfast Meeting 12/3/99
C80	Krueger, 1999, "Phase II trial results of Amevive TM (LFA3TIP) in patients with chronic plaque psoriasis," Br. J. Dermatol. 141:979-980, Abstract 39
C81	Kutemeier et al., 1994, "Assembly of humanized antibody genes from synthetic oligonucleotides using a single-round PCR," Biotechniques 17:242-246
C82	Lafaille et al., 1994, "High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice," Cell 78(3):399-408
C83	Langer and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem. 23:61
C84	Latinne et al., 1997, "BTI-322, An Anti-Human CD2 MAB, Elicits Specific Depletion of T Cells Activated by Anti-TCR VbMAB," Abstract form for: The American Society of Transplant Physicians, 15 th Annual Scientific Meeting May 10-14
C85	Latinne et al., 1996, "An anti-CD2 mAb induces immunosuppression and hyporesponsiveness of CD2+ human T cells in vitro," Int. Immunol. 8:1113-1119
C86	Lebwohl, 2000, "Advances in psoriasis therapy," Dermatol. Clin. 18:13-19
C87	Lerut et al., "The Use of Tacrolimus (TAC) and Anti-CD2 Antibody Lo-CD2a (BTI-322) in Adult Liver Transplantation (LT): Preliminary Results of a Prospective Randomized Study," Abstract 102
C88	Levy et al., 1985, "Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate," Science 228:190-192
C89	Li et al., 1995, "CD2 Antigen: Signaling Features and Strategies to Inhibit CD2 Antigen-Derived Signals," in Recent Developments in Transplantation Medicine V.2, Ch. 7, Salomon and Sollinger, eds., pp. 97-121
C90	Magilavy et al., "Immunopharmacologic effects of AMEVIVE TM (LFA3TIP) in chronic plaque psoriasis: Selectivity for peripheral memory effector (CD45RO+) over naïve (CD45RA+) T cells," Poster presentation and abstract from Br. J. Dermatol. 141:990, Abstract 81
C91	Magilavy et al., 2000, "The Response of Plaque Psoriasis to Amevive TM (LFA3TIP) and the Selective Suppression of Memory/Effector T Cells (CD45RO+) Verses Naïve T Cells (CD45RA+) Is Serum Levels of LFA3TIP," J. Invest.

		Dermatol. 114(4):776 Abstract 148
	C92	Magilavy et al., 1999, "Pharmacodynamic effects of Amevive™ (LFA3TIP), a LFA-3/igg Fc fusion protein in chronic plaque psoriasis: selectivity for peripheral memory-effector (CD45RO+) over naïve (CD45RA+) T cells," Amevive Breakfast Meeting, 12/3/99
	C93	Majeau et al., 1994, "Mechanism of Lymphocyte Function-Associated Molecule 3-Ig Fusion Proteins Inhibition of T Cell Responses," J. Immunol. 152(6):2753-67
	C94	Margolis et al., 2000, "Pentostatin: A novel treatment for steroid refractory acute GHVD," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Poster Board Number 774
	C95	Meier et al., 1995, "Immunomodulation by LFA3TIP, an LFA-3/IgG1 Fusion Protein: Cell Line Dependent Glycosylation Effects on Pharmacokinetics and Pharmacodynamic Markers," Ther. Immunol. 2(3):159-171
	C96	Merck Manual of Diagnosis and Therapy, Seventeenth Edition. Ed. Beers and Berkow. Merck Research Laboratories (Whitehouse Station, NJ), 1999, pages 416-423
	C97	Miller et al., 1993, "Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses," J. Exp. Med. 178:211-222
	C98	Min et al., 1996, "Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice," Cancer Res. 56:2428-2433
	C99	Mollee et al., 2000, "Combination therapy with antithymocyte globulin (ATG) and tacrolimus for patients with steroid refractory GHVD," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00
	C100	Mollereau et al., 1999, "Effects of Anti-CD2 Monoclonal Antibody: CD2- and CD95-Mediated Apoptosis of Human Peripheral T Cells," Transplantation Proc. 31:1245
	C101	Mourad et al., 1997, "BTI-322 for Acute Rejection After Renal Transplantation," Transplantation Proc. 29:2353
	C102	Nevitt and Hutchinson, 1996, "Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease," Brit. J. Dermatol. 135:533-537
	C103	Ning et al., 1996, "Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel," Radiother. Oncol. 39:179-189
	C104	Nizet et al., 2000, "The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322," Transplantation 69(7):1420-1428
	C105	Oi et al., 1986, BioTechniques 4:214
	C106	Order, 1985, "Analysis, results and future prospective of the therapeutic use of radiolabeled antibody in cancer therapy," in: <i>Monoclonal Antibodies for Cancer Detection and Therapy</i> , Baldwin et al., eds., Academic Press, pp. 303-316
	C107	O'Reilly et al., 1999, "Antiangiogenic activity of the cleaved conformation of the serpin antithrombin," Science 285:1926-1928
	C108	Ortonne, 1999, "Recent Developments in the Understanding of the Pathogenesis of Psoriasis," Br. J. Dermatol. 140 Suppl 54:1-7
	C109	Oswald et al., 1992, "Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation," Proc. Natl. Acad. Sci. USA 89:8676-8680
	C110	Papp et al., 1999, "The treatment of moderate to severe psoriasis with hul 124: a new monoclonal antibody," Br. J. Dermatol. 141:980, Abstract 40
	C111	Pasquini et al., 2000, "Basiliximab (BaMab) - a selective interleukin-2 receptor (IL-2R) antagonist - as therapy for refractory acute Graft Versus Host Disease (a-GHVD) following bone marrow transplantation (BMT)," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Poster Board No. 762
	C112	Paul, ed., 1989, <i>Fundamental Immunology</i> 2 nd Ed., Raven Press, NY, pp. 332-336
	C113	Peters et al., 2000, "Pathophysiology and treatment of psoriasis," Am. J. Health Sys. Pharm. 57:645-659
	C114	Phillips et al., 1993, "Infectious agents in chronic rheumatic diseases," in: <i>Arthritis and Allied Conditions: A Textbook of Rheumatology</i> , Lee & Febiger, eds., Chapter 30
	C115	Potter et al., 2000, "Campath 1 H "In the Bag" is an effective method of GHVD prevention in allogeneic stem cell transplantation," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Location 305
	C116	Przepiorika et al., "Pharmacokinetics and Safety of BTI-322, a Rat Anti-CD2 Monoclonal Antibody for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease," BTI Ref 3623
	C117	Przepiorka et al., 1998, "A Phase II Study of BTI-322, a Monoclonal Anti-CD2 Antibody, for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease," Blood 92(11):4066-4071
	C118	Rabinowitz et al., 1995, "In vitro activation leads to the binding of T-cell markers to the surface of B-lymphocytes," Clin. Immunol. Immunopathol. 76:148-154
	C119	Ratanathathorn et al., 1999, "Pharmacokinetics and Safety of Medi-507, a Humanized Anti-CD2 Monoclonal Antibody in Severe Steroid-Resistant Graft-Versus-Host Disease," International Society for Experimental Hematology, Abstract 119
	C120	Robert et al., 1999, "Inflammatory skin diseases, T cells, and immune surveillance," New England J of Med. 341(24):1817-1828
	C121	Roenigk et al., 1988, "Methotrexate in psoriasis: revised guidelines," J. Am. Acad. Dermatol. 19(1 pt. 1):145-156
	C122	Rouleau et al., 1997, "CD2 Induced Apoptosis of Peripheral T Cells," Transplantation Proc. 29:2377-2378
	C123	Saudek et al., 1989, "A preliminary trial of the programmable implantable medication system for insulin delivery," N. Engl. J. Med. 321:574-579
	C124	Schad et al., 1996, "An Anti-CD2 Monoclonal Antibody That Elicits Alloantigen-Specific Hyporesponsiveness,"

		Transplantation Proceedings 28(4):2051-2053
	C125	Seckinger et al., 1990, "Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor," Proc. Natl. Acad. Sci. USA 87:5188-5192
	C126	Spitzer et al., 2000, "Haploidentical donor bone marrow transplantation for advanced hematologic malignancy following non-myeloablative preparative therapy: role of in vivo T cell depletion with anti-thymocyte globulin or anti-CD2 monoclonal antibody therapy," Blood 96:841A
	C127	Squifflet et al., 1997, "BTI-322 for Induction Therap after Renal Transplantation: A Randomized Study," Transplant Proc. 29(1-2):317-319
	C128	Squifflet et al., 1997, "A Randomized Study of BTI-322 for the Prevention of Renal Allograft Rejection: One Year Follow Up," Abstract form for: The American Society of Transplant Physicians, 15 th Annual Scientific Meeting May 10-14
	C129	Stern, 1995, "Epidemiology of psoriasis," Dermatol. Clin. 13:717-722
	C130	Stern and Laird, 1994, "The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study," Cancer 73:2759-2764
	C131	Strober, 1985, "Animal models of inflammatory bowel disease--an overview," Dig. Dis. Sci. 30(12 suppl.):3S-10S
	C132	Sultan et al., 1997, "Blockade of CD2-LFA-3 Interactions Protects Human Skin ALlografts in Immunodeficient Mouse/Human Chimeras," Nature Biotechnology 15:759-762
	C133	Takahashi et al., 1994, "Human Fas ligand: gene structure, chromosomal location and species specificity," Int. Immunol. 6:1567-1574
	C134	Thorbecke et al., 1992, "Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice," Proc. Natl. Acad. Sci. USA 89:7375-7379
	C135	Thorpe, 1985, "Antibody carriers of cytotoxic agents in cancer therapy: a review," in: <i>Monoclonal Antibodies '84: Biological and Clinical Applications</i> , Pinchera et al., eds., pp. 475-506
	C136	Thorpe and Ross, 1982, "The preparation and cytotoxic properties of antibody-toxin conjugates," Immunol. Rev. 62:119-158
	C137	Trauneker et al., 1988, "Soluble CD4 molecules neutralize human immunodeficiency virus type 1," Nature 331:84-86
	C138	Trentham et al., 1977, "Autoimmunity to type II collagen an experimental model of arthritis," J. Exp. Med. 146(3):857-868
	C139	Tutt et al., 1991, "Trispecific F(ab') ₃ derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells," J. Immunol. 147:60-69
	C140	Vie et al., 1992, "Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor," Proc. Natl. Acad. Sci. USA 89:11337-11347
	C141	Williams et al., 1994, "Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis," Proc. Natl. Acad. Sci. USA 91:2762-2766
	C142	Winter et al., 1962, "Carrageenan-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs," Proc. Soc. Exp. Biol. Med. 111:544-547
	C143	Woodward et al., 1996, "Blockade of multiple costimulatory receptors induces hyporesponsiveness," Transplantation 62(7):1011-1018
	C144	Wu et al., 1998, "Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb," Proc. Natl. Acad. Sci. USA 95:6037-6042
	C145	Wu and Wu, 1987, "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," J. Biol. Chem. 262:4429-4432
	C146	Xu et al., 2000, "Inhibition of Human Anti-Pig T Cell Response by Anti-CD2, Anti-CD40L, and CTLA4-Ig: A Comparative Study," Transplantation Proc. 32:926
	C147	Yamamoto et al., 1998, "The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats," Endocrinol. 139:1411-1419
	C148	Yokota et al., 1986, "Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities," Proc. Natl. Acad. Sci. USA 83:5894-5898
	C149	Yoshitake et al., 1999, "Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption," Proc. Natl. Acad. Sci. USA 96:8156-8160
	C150	Zamvil and Steinman, 1990, "The T lymphocyte in experimental allergic encephalomyelitis," Annu. Rev. Immunol. 8:579-621
	C151	Zheng et al., 1995, "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation," J. Immunol. 154:5590-5600
EXAMINER		DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		